3D printing injectable microbeads using a composite liposomal ink for local treatment of peritoneal diseases
R Eugster, AA Ganguin, A Seidi, S Aleandri… - Drug delivery and …, 2024 - Springer
The peritoneal cavity offers an attractive administration route for challenging-to-treat
diseases, such as peritoneal carcinomatosis, post-surgical adhesions, and peritoneal …
diseases, such as peritoneal carcinomatosis, post-surgical adhesions, and peritoneal …
Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma
D Zhang, X Tian, Y Wang, F Liu, J Zhang, H Wang… - Phytomedicine, 2024 - Elsevier
Background Lung adenocarcinoma (LUAD) is the most common pathological type of lung
cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been …
cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been …
Development of Erlotinib-Loaded Nanotransferosomal Gel for the Topical Treatment of Ductal Carcinoma in Situ
Aims: This study was aimed to formulate erlotinib (ERL)-loaded transferosomal gel (ERL@
TG) intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
TG) intended for topical application for the treatment of ductal carcinoma in situ. Materials & …
Establishment of a novel microfluidic co-culture system for simultaneous analysis of multiple indicators of gefitinib sensitivity in colorectal cancer cells
X Li, W Li, J Wang, Q Wang, M Liang, S Chen, W Ba… - Microchimica Acta, 2024 - Springer
The therapeutic effect of gefitinib on colorectal cancer (CRC) is unclear, but it has been
reported that stromal cells in the tumor microenvironment may have an impact on drug …
reported that stromal cells in the tumor microenvironment may have an impact on drug …
Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF
X Song, L Wang, P Cai, Y Xu, Q Liu, D Fan - Toxicology and Applied …, 2024 - Elsevier
Drug resistance is a serious problem for gefitinib in the treatment of lung cancer.
Ginsenoside CK, a metabolite of diol ginsenosides, have many excellent pharmacological …
Ginsenoside CK, a metabolite of diol ginsenosides, have many excellent pharmacological …
[PDF][PDF] 糖酵解在非小细胞肺癌吉非替尼耐药中的作用研究
李楠， 路晨阳， 祝阿妮， 杨栋才， 马倩， 严奉奇… - 中国癌症防治 …, 2024 - zgazfz.com
目的探讨糖酵解在非小细胞肺癌(non⁃ small cell lung cancer, NSCLC) 吉非替尼(Gefitinib)
耐药中的变化及作用. 方法体外培养NSCLC 亲本细胞PC⁃ 9 和A549, 并采用浓度递增法构建 …
耐药中的变化及作用. 方法体外培养NSCLC 亲本细胞PC⁃ 9 和A549, 并采用浓度递增法构建 …
[HTML][HTML] 吉非替尼与TRAIL 协同诱导A549 人肺腺癌细胞系凋亡的作用研究
程广东， 魏煜程 - Advances in Clinical Medicine, 2024 - hanspub.org
目的: 本论文旨在探讨吉非替尼与肿瘤坏死因子相关凋亡诱导配体TRAIL (TNF-Related
Apoptosis Inducing Ligand) 的协同抗人肺癌作用并阐明两者协同的机制. 方法 …
Apoptosis Inducing Ligand) 的协同抗人肺癌作用并阐明两者协同的机制. 方法 …
Analysis of DHX32 as diagnostic gene and independent prognostic factor of lung squamous cell carcinoma
Z Zuo, D Jin, H Li, W Min, J Zhang, Z Lin, Y Gou - 2024 - researchsquare.com
Background: The abnormal of DHX32 was related to the occurrence, development and
clinicopathological features of cancer, but DHX32 has not been studied in Lung squamous …
clinicopathological features of cancer, but DHX32 has not been studied in Lung squamous …